Extended Kelvin theorem in relativistic magnetohydrodynamics

We prove the existence of a generalization of Kelvin's circulation theorem in general relativity which is applicable to perfect isentropic magnetohydrodynamic flow. The argument is based on a new version of the Lagrangian for perfect magnetohydrodynamics. We illustrate the new conserved circulation with the example of a relativistic magnetohydrodynamic flow possessing three symmetries.Comment: Invited talk at IARD 2000, the Second International Conference on Relativistic Dynamics, Bar-Ilan University, Israel, 26-28 June, 2000. To appear in the proceedings in a special issue of Foundations of Physic

Can a Lender of Last Resort Stabilize Financial Markets? Lessons from the Founding of the Fed

We use the founding of the Federal Reserve as a historical experiment to provide some insight into whether a lender of last resort can stabilize financial markets. Following the Panic of 1907, Congress passed two measures that established a lender of last resort in the United States: (1) the Aldrich-Vreeland Act of 1908 which authorized certain banks to issue emergency currency during a financial crisis and (2) the Federal Reserve Act of 1913 which established a central bank. We employ a new identification strategy to isolate the effects of the introduction of a lender of last resort from other macroeconomic shocks. We compare the standard deviation of stock returns and short-term interest rates over time across the months of September and October, the two months of the year when financial markets were most vulnerable to a crash because of financial stringency from the harvest season, with the rest of the year during the period 1870-1925. Stock volatility in the post-1907 period (June 1908-1925) was more than 40 percent lower in the months of September and October compared to the period (1870- May 1908). We also find that the volatility of the call loan rate declined nearly 70 percent in September and October following the monetary regime change.

The Correlation of Spectral Lag Evolution with Prompt Optical Emission in GRB 080319B

We report on observations of correlated behavior between the prompt gamma-ray and optical emission from GRB 080319B, which confirm that (i) they occurred within the same astrophysical source region and (ii) their respective radiation mechanisms were dynamically coupled. Our results, based upon a new CCF methodology for determining the time-resolved spectral lag, are summarized as follows. First, the evolution in the arrival offset of prompt gamma-ray photon counts between Swift-BAT 15-25 keV and 50-100 keV energy bands (intrinsic gamma-ray spectral lag) appears to be anti-correlated with the arrival offset between prompt 15-350 keV gamma-rays and the optical emission observed by TORTORA (extrinsic optical/gamma-ray spectral lag), thus effectively partitioning the burst into two main episodes at ~T+28+/-2 sec. Second, the rise and decline of prompt optical emission at ~T+10+/-1 sec and ~T+50+/-1 sec, respectively, both coincide with discontinuities in the hard to soft evolution of the photon index for a power law fit to 15-150 keV Swift-BAT data at ~T+8+/-2 sec and ~T+48+/-1 sec. These spectral energy changes also coincide with intervals whose time-resolved spectral lag values are consistent with zero, at ~T+12+/-2 sec and ~T+50+/-2 sec. These results, which are robust across heuristic permutations of Swift-BAT energy channels and varying temporal bin resolution, have also been corroborated via independent analysis of Konus-Wind data. This potential discovery may provide the first observational evidence for an implicit connection between spectral lags and GRB emission mechanisms in the context of canonical fireball phenomenology. Future work includes exploring a subset of bursts with prompt optical emission to probe the unique or ubiquitous nature of this result.Comment: 6 pages, 3 figures. Contributed to the Proceedings of the Sixth Huntsville GRB Symposium. Edited by C.A. Meegan, N. Gehrels, and C. Kouvelioto

Tocotrienols-induced inhibition of platelet thrombus formation and platelet aggregation in stenosed canine coronary arteries

<p>Abstract</p> <p>Background</p> <p>Dietary supplementation with tocotrienols has been shown to decrease the risk of coronary artery disease. Tocotrienols are plant-derived forms of vitamin E, which have potent anti-inflammatory, antioxidant, anticancer, hypocholesterolemic, and neuroprotective properties. Our objective in this study was to determine the extent to which tocotrienols inhibit platelet aggregation and reduce coronary thrombosis, a major risk factor for stroke in humans. The present study was carried out to determine the comparative effects of α-tocopherol, α-tocotrienol, or tocotrienol rich fraction (TRF; a mixture of α- + γ- + δ-tocotrienols) on <it>in vivo platelet thrombosis </it>and <it>ex vivo </it>platelet aggregation (PA) after intravenous injection in anesthetized dogs, by using a mechanically stenosed circumflex coronary artery model (Folts' cyclic flow model).</p> <p>Results</p> <p>Collagen-induced platelet aggregation (PA) in platelet rich plasma (PRP) was decreased markedly after treatment with α-tocotrienol (59%; <b><it>P </it></b>< 0.001) and TRF (92%; <b><it>P </it></b>< 0.001). α-Tocopherol treatment was less effective, producing only a 22% (<b><it>P </it></b>< 0.05) decrease in PA. Adenosine diphosphate-induced (ADP) PA was also decreased after treatment with α-tocotrienol (34%; <b><it>P </it></b>< 0.05) and TRF (42%; <b><it>P </it></b>< 0.025). These results also indicate that intravenously administered tocotrienols were significantly better than tocopherols in inhibiting cyclic flow reductions (CFRs), a measure of the acute platelet-mediated thrombus formation. Tocotrienols (TRF) given intravenously (10 mg/kg), abolished CFRs after a mean of 68 min (range 22 -130 min), and this abolition of CFRs was sustained throughout the monitoring period (50 - 160 min).</p> <p>Next, pharmacokinetic studies were carried out and tocol levels in canine plasma and platelets were measured. As expected, α-Tocopherol treatment increased levels of total tocopherols in post- vs pre-treatment specimens (57 vs 18 μg/mL in plasma, and 42 vs 10 μg/mL in platelets). However, treatment with α-tocopherol resulted in slightly decreased levels of tocotrienols in post- vs pre-treatment samples (1.4 vs 2.9 μg/mL in plasma and 2.3 vs 2.8 μg/mL in platelets). α-Tocotrienol treatment increased levels of both tocopherols and tocotrienols in post- vs pre-treatment samples (tocopherols, 45 vs 10 μg/mL in plasma and 28 vs 5 μg/mL in platelets; tocotrienols, 2.8 vs 0.9 μg/mL in plasma and 1.28 vs 1.02 μg/mL in platelets). Treatment with tocotrienols (TRF) also increased levels of tocopherols and tocotrienols in post- vs pre-treatment samples (tocopherols, 68 vs 20 μg/mL in plasma and 31.4 vs 7.9 μg/mL in platelets; tocotrienols, 8.6 vs 1.7 μg/mL in plasma and 3.8 vs 3.9 μg/mL in platelets).</p> <p>Conclusions</p> <p>The present results indicate that intravenously administered tocotrienols inhibited acute platelet-mediated thrombus formation, and collagen and ADP-induced platelet aggregation. α-Tocotrienols treatment induced increases in α-tocopherol levels of 4-fold and 6-fold in plasma and platelets, respectively. Interestingly, tocotrienols (TRF) treatment induced a less pronounced increase in the levels of tocotrienols in plasma and platelets, suggesting that intravenously administered tocotrienols may be converted to tocopherols. Tocotrienols, given intravenously, could potentially prevent pathological platelet thrombus formation and thus provide a therapeutic benefit in conditions such as stroke and myocardial infarction.</p

Distinct immune signatures in directly treated and distant tumors result from TLR adjuvants and focal ablation.

Both adjuvants and focal ablation can alter the local innate immune system and trigger a highly effective systemic response. Our goal is to determine the impact of these treatments on directly treated and distant disease and the mechanisms for the enhanced response obtained by combinatorial treatments. Methods: We combined RNA-sequencing, flow cytometry and TCR-sequencing to dissect the impact of immunotherapy and of immunotherapy combined with ablation on local and systemic immune components. Results: With administration of a toll-like receptor agonist agonist (CpG) alone or CpG combined with same-site ablation, we found dramatic differences between the local and distant tumor environments, where the directly treated tumors were skewed to high expression of F4/80, Cd11b and Tnf and the distant tumors to enhanced Cd11c, Cd3 and Ifng. When ablation was added to immunotherapy, 100% (n=20/20) of directly treated tumors and 90% (n=18/20) of distant tumors were responsive. Comparing the combined ablation-immunotherapy treatment to immunotherapy alone, we find three major mechanistic differences. First, while ablation alone enhanced intratumoral antigen cross-presentation (up to ~8% of CD45+ cells), systemic cross-presentation of tumor antigen remained low. Combining same-site ablation with CpG amplified cross-presentation in the draining lymph node (~16% of CD45+ cells) compared to the ablation-only (~0.1% of CD45+ cells) and immunotherapy-only cohorts (~10% of CD45+ cells). Macrophages and DCs process and present this antigen to CD8+ T-cells, increasing the number of unique T-cell receptor rearrangements in distant tumors. Second, type I interferon (IFN) release from tumor cells increased with the ablation-immunotherapy treatment as compared with ablation or immunotherapy alone. Type I IFN release is synergistic with toll-like receptor activation in enhancing cytokine and chemokine expression. Expression of genes associated with T-cell activation and stimulation (Eomes, Prf1 and Icos) was 27, 56 and 89-fold higher with ablation-immunotherapy treatment as compared to the no-treatment controls (and 12, 32 and 60-fold higher for immunotherapy-only treatment as compared to the no-treatment controls). Third, we found that the ablation-immunotherapy treatment polarized macrophages and dendritic cells towards a CD169 subset systemically, where CD169+ macrophages are an IFN-enhanced subpopulation associated with dead-cell antigen presentation. Conclusion: While the local and distant responses are distinct, CpG combined with ablative focal therapy drives a highly effective systemic immune response

Phase Space Approach to Solving the Time-independent Schr\"odinger Equation

We propose a method for solving the time independent Schr\"odinger equation based on the von Neumann (vN) lattice of phase space Gaussians. By incorporating periodic boundary conditions into the vN lattice [F. Dimler et al., New J. Phys. 11, 105052 (2009)] we solve a longstanding problem of convergence of the vN method. This opens the door to tailoring quantum calculations to the underlying classical phase space structure while retaining the accuracy of the Fourier grid basis. The method has the potential to provide enormous numerical savings as the dimensionality increases. In the classical limit the method reaches the remarkable efficiency of 1 basis function per 1 eigenstate. We illustrate the method for a challenging two-dimensional potential where the FGH method breaks down.Comment: 5 figures. Includes supplementary material. arXiv admin note: substantial text overlap with arXiv:1010.258